gardasil
| 4:52PM 1/14/2010
Merck shares rose more than 6% in two days as investors reacted to an analyst's upgrade and news that the drugmaker is trying to broaden the market for its human papillomavirus/cervical cancer vaccine, Gardasil.
| 5:30PM 9/29/2009
Just when GlaxoSmithKline (GSK) was set for U.S. Food & Drug Administration approval of its cervical cancer vaccine, tragedy struck in the United Kingdom. Natalie Morton, a 14-year-old British girl, died Monday a few hours after receiving the vaccine, called Cervarix. On Tuesday, the FDA...
| 2:30PM 8/19/2009
As if Merck & Co. (MRK) needed more scrutiny of its controversial cervical cancer vaccine, Gardasil.
One of the first cancer vaccines on the market, Gardasil combats human papillomavirus -- a sexually transmitted virus contracted by 80 percent of sexually active women by age 50 -- Gardasil was...
| 1:30PM 6/05/2009
Major drug companies are declining more than the general market today, but none like Merck & Co. (MRK). Merck's shares dropped 2.5 percent on news it won't seek approval this year for its heart-failure drug rolofylline after preliminary results of a Phase III study failed to meet...